Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
UBS ETF - Bloomberg Barclays US Liquid Corporates UCITS ETF Market Cap
The UBS ETF - Bloomberg Barclays US Liquid Corporates UCITS ETF (CBUS) share price is expected to increase by 320.48% over the next year. This is based on calculating the average 12-month share price estimate provided by 4 stock analysts who have covered CBUS. Price targets range from $5 at the low end to $25 at the high end. The current analyst consensus for CBUS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 4 Wall Street analysts have assignedCBUS 3 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect UBS ETF - Bloomberg Barclays US Liquid Corporates UCITS ETF to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CBUS. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CBUS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Amit Dayal HC Wainwright & Co. | Buy | $25 | Reiterates | Nov 11, 2024 |
| Austin Moeller Canaccord Genuity | Buy | $20 | Maintains | Oct 22, 2024 |
| Matthew Venezia Alliance Global Partners | Buy | $23.5 | Maintains | Sep 24, 2024 |
| Austin Moeller Canaccord Genuity | Buy | $20 | Maintains | Sep 19, 2024 |
| Austin Moeller Canaccord Genuity | Buy | $21 | Maintains | Aug 12, 2024 |
| Matthew Venezia Alliance Global Partners | Buy | $25 | Initiates | Jul 29, 2024 |
| Austin Moeller Canaccord Genuity | Buy | $22 | Assumes | Jul 19, 2024 |
| Amit Dayal HC Wainwright & Co. | Buy | $25 | Reiterates | May 10, 2024 |
| Amit Dayal HC Wainwright & Co. | Buy | $25 | Maintains | Mar 22, 2024 |
| Amit Dayal HC Wainwright & Co. | Buy | $25 | Reiterates | Oct 9, 2023 |
When did it IPO
2017
Staff Count
183
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Rory Balfour Riggs M.B.A.
Market Cap
$129.2M
In 2023, CBUS generated $1.8M in revenue, which was a increase of 1,057.32% from the previous year. This can be seen as a signal that CBUS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Tue, 19 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cibus and Biographica are collaborating to identify gene editing targets for Cibus' development of disease resistance traits.
Why It Matters - The collaboration could accelerate Cibus' product development, enhancing its competitive edge in biotech and potentially increasing market value, influencing investor sentiment.
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Cibus, Inc. (Nasdaq: CBUS) CEO Rory Riggs will attend the 13th Annual Roth Technology Conference, as announced on November 18, 2024.
Why It Matters - Rory Riggs' participation in the Roth Technology Conference signals potential visibility and credibility for Cibus, which may attract investor interest and impact stock performance.
Sat, 09 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Cibus, Inc. (NASDAQ: CBUS) will hold its Q3 2024 earnings conference call on November 7, 2024, at 4:30 PM ET, featuring key executives including CFO Carlo Broos and CEO Rory Riggs.
Why It Matters - Cibus's Q3 2024 results call provides insights into financial performance and strategic direction, influencing investor sentiment and stock valuation.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The company is realigning its strategy to focus on advancing its weed management platform for Rice, Pod Shatter Reduction in Canola, and Sclerotinia resistance in Canola and Soybean.
Why It Matters - The strategic realignment signals a focused investment in key agricultural technologies, potentially enhancing market competitiveness and driving future revenue growth in targeted sectors.
Thu, 07 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Cibus (CBUS) reported Q3 earnings of $0.06 per share, surpassing the Zacks estimate of a $0.90 loss, and improving from a $1.59 loss per share a year prior.
Why It Matters - Cibus's earnings beat expectations significantly, indicating improved financial health and operational efficiency, which could boost investor confidence and stock performance.
Tue, 05 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The greenhouse results indicate a significant milestone in the development of the second-generation HT2 edited Canola.
Why It Matters - Successful greenhouse results for HT2 edited Canola indicate progress in agricultural innovation, potentially enhancing yield and profitability, impacting market competitiveness and stock valuations.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
